NFKB1 and early-onset autosomal dominant Alzheimer disease: Research has shown that vascular dysfunction caused by atherosclerosis can disrupt the blood–brain barrier, induce inflammation, and impede β-amyloid clearance.[102] The NF-κB signaling pathway and VEGF signaling pathway are also involved in the AD process, in addition to the pathways mentioned above.[103–105] In conclusion, our network pharmacology analysis suggests that Polygonatum has the potential to treat Alzheimer’s disease through a multi-component, multi-target, and multi-pathway approach.